Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
* Treatment of duodenal ulcers and gastric ulcers.
* Eradication of *Helicobacter pylori* infection (in combination with antibiotics).
## Adult Dosing
* **Erosive Esophagitis:** 40 mg orally or IV once daily for up to 8 weeks.
* **Maintenance of Healing Erosive Esophagitis:** 40 mg orally once daily.
* **Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Starting dose is typically 40 mg orally or IV twice daily. Doses may be increased as clinically indicated. Doses up to 240 mg IV daily have been administered.
* **Duodenal Ulcers:** 40 mg orally once daily for up to 4 weeks.
* **Gastric Ulcers:** 40 mg orally once daily for up to 4 weeks.
* ***H. pylori* Eradication:** 40 mg orally twice daily in combination with clarithromycin and amoxicillin for 7-14 days.
## Pediatric Dosing
Dosing in pediatric patients varies by indication and age. Specific dosing should be guided by age, weight, and clinical judgment, often referencing institutional protocols.
* **Erosive Esophagitis (5-16 years):** 20-40 mg orally once daily.
* **Erosive Esophagitis (1 month to <5 years):** Dosing is weight-based, typically 0.6-1.1 mg/kg/day orally. Consult specific pediatric guidelines.
## Dose Adjustments
* **Hepatic Impairment:** Maximum daily oral dose of 20 mg for patients with severe hepatic impairment. IV doses should also be reduced.
## Contraindications
* Known hypersensitivity to pantoprazole, any component of the formulation, or other substituted benzimidazoles.
## Adverse Effects
Common: Diarrhea, headache, nausea, abdominal pain, dizziness, flatulence.
Serious:
* Long-term use: Increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, vitamin B12 deficiency.
* Acute interstitial nephritis.
* Systemic lupus erythematosus.
## Key Drug Interactions
* **Drugs Dependent on Gastric pH for Absorption:** May decrease absorption of drugs like ketoconazole, itraconazole, posaconazole, iron salts, and vitamin B12.
* **Methotrexate:** May increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 Substrates:** May affect metabolism of drugs like clopidogrel.
* **Atazanavir and Nelfinavir:** Coadministration is not recommended.
## Monitoring
* Monitor for signs and symptoms of *Clostridium difficile*-associated diarrhea.
* Monitor serum magnesium levels, especially in patients on long-term therapy or concomitant medications that may cause hypomagnesemia.
* Monitor for bone fracture risk.
* Consider vitamin B12 levels in patients with prolonged therapy.
## Clinical Pearls
* Pantoprazole is generally considered more stable in acidic environments compared to some other PPIs.
* IV administration may be preferred in patients unable to take oral medications or with severe GI bleeding.
* Long-term use should be reserved for situations where continued acid suppression is necessary and the benefits outweigh the risks.
***
**Disclaimer:** This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines for complete details, including specific indications, contraindications, warnings, precautions, and adverse reactions, before prescribing or administering any medication. Dosing may vary based on individual patient factors and local institutional protocols.
